Strattera (Atomoxetine) Indications
Strattera is FDA-approved for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children (ages 6 and older), adolescents, and adults. 1
Primary Indication: ADHD Treatment
Strattera (atomoxetine) is a selective norepinephrine reuptake inhibitor that functions as a nonstimulant medication for ADHD 1. It works by inhibiting the presynaptic norepinephrine transporter, increasing norepinephrine availability in the prefrontal cortex to improve attention, reduce impulsiveness, and decrease hyperactivity 1, 2.
Key Clinical Features:
- Approved age range: Children ≥6 years, adolescents, and adults 3, 1
- Not a controlled substance: Unlike stimulants, atomoxetine has negligible abuse potential and is not classified as a controlled substance 2, 4, 5
- Dosing flexibility: Can be administered once daily or split into two divided doses (morning and late afternoon/evening) 3, 1
Position in Treatment Guidelines
According to the 2019 American Academy of Pediatrics guidelines, atomoxetine is classified as a nonstimulant medication option for ADHD, alongside guanfacine and clonidine 3. The 2024 Asian ADHD guidelines similarly list Strattera as an approved nonstimulant option across multiple countries including Japan, Malaysia, Singapore, India, and South Korea 6.
When to Consider Atomoxetine:
Atomoxetine is particularly useful as a first-line option in patients who:
- Are at risk for substance abuse or have active substance use disorders 2, 4, 5
- Have comorbid anxiety disorders 2
- Have comorbid tic disorders 2
- Prefer not to take a controlled substance 4, 5
- Cannot tolerate stimulant side effects (particularly insomnia) 2
Atomoxetine can also serve as adjunctive therapy when combined with stimulants if monotherapy is insufficient, though this is off-label use with limited evidence 3.
Efficacy Considerations
While atomoxetine demonstrates significantly greater efficacy than placebo in reducing ADHD symptoms 2, 4, 5, head-to-head trials show it is less effective than extended-release stimulants (OROS methylphenidate and mixed amphetamine salts XR) 2, 7. However, it shows comparable efficacy to immediate-release methylphenidate 2, 7.
Response Characteristics:
- Improves attention, impulsiveness, and hyperactivity 1, 2
- Effects persist throughout the day with once-daily dosing 2
- No symptom rebound upon discontinuation 2
- Benefits extend to health-related quality of life 2
Critical Safety Warnings
The FDA requires a black box warning for suicidal ideation in children and adolescents. Pooled analyses showed 0.4% of atomoxetine-treated patients developed suicidal thoughts versus 0% on placebo 1. Close monitoring is mandatory, especially during treatment initiation and dose adjustments 1.
Additional Important Safety Considerations:
- Severe liver damage (rare but serious): Monitor for jaundice, dark urine, right upper quadrant pain, or unexplained flu-like symptoms 1
- Cardiovascular effects: Increases heart rate and blood pressure; obtain cardiac history and consider ECG if risk factors present 3
- Growth effects: May cause initial growth delays that normalize after 2-3 years 3
Common Adverse Effects:
Headache, abdominal pain, decreased appetite, nausea, vomiting, somnolence (more common than with stimulants), and gastrointestinal symptoms 3, 2
Pharmacokinetic Considerations
CYP2D6 metabolism significantly affects atomoxetine exposure 8. Poor metabolizers (7-10% of population) have 10-fold higher plasma concentrations and longer half-life (21.6 hours vs 5.2 hours in extensive metabolizers) 8. However, efficacy and tolerability remain similar regardless of metabolizer status 2, 8.
Concomitant use of CYP2D6 inhibitors (e.g., paroxetine, fluoxetine) mimics poor metabolizer pharmacokinetics and may require dose adjustment 8.